# Royalty Pharma plc (RPRX) FY2024 Annual Statement of Cash Flows

- Company: Royalty Pharma plc (RPRX)
- Period: 2024-01-01 to 2024-12-31
- Filing: FY2024 10-K, filed 2025-02-12, accession number 0001802768-25-000010
- Page: https://plicit.ai/financials/rprx/fy2024-annual-cash-flow
- Chart image: https://plicit.ai/charts/rprx-fy2024-annual-cash-flow-sankey.png

## Chart details

Cash flows for Jan 1, 2024 through Dec 31, 2024. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2023. Ending cash: Dec 31, 2024. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

- **Beginning cash on Dec 31, 2023**: 477,010,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
- **Operating activities**: 2,768,986,000 US dollars. Net cash provided.
- **Cash collections from financial royalty assets**: 2,983,410,000 US dollars
- **Cash collections from intangible royalty assets**: 14,647,000 US dollars
- **Other royalty cash collections**: 108,846,000 US dollars
- **Interest received**: 46,482,000 US dollars
- **Distributions from equity method investees**: 13,396,000 US dollars
- **Development-stage funding payments - ongoing**: negative 2,000,000 US dollars
- **Payments for operating and professional costs**: negative 236,225,000 US dollars
- **Interest paid**: negative 159,570,000 US dollars
- **Development-stage funding payments - upfront and milestone**: 0 US dollars
- **Investing activities**: negative 2,678,115,000 US dollars. Net cash used.
- **Distributions from equity method investees**: 23,641,000 US dollars
- **Purchases of available for sale debt securities**: negative 150,000,000 US dollars
- **Purchases of equity securities**: negative 62,500,000 US dollars
- **Proceeds from available for sale debt securities**: 19,786,000 US dollars
- **Purchases of marketable securities**: 0 US dollars
- **Proceeds from sales and maturities of marketable securities**: 0 US dollars
- **Investments in equity method investees**: negative 10,955,000 US dollars
- **Acquisitions of financial royalty assets**: negative 2,505,701,000 US dollars
- **Milestone payments**: negative 75,000,000 US dollars
- **Proceeds from equity securities**: 98,575,000 US dollars
- **Acquisitions of other financial assets**: negative 18,000,000 US dollars
- **Other**: 2,039,000 US dollars
- **Financing activities**: 361,145,000 US dollars. Net cash provided.
- **Distributions to legacy non-controlling interests - Portfolio Receipts**: negative 362,280,000 US dollars
- **Distributions to continuing non-controlling interests**: negative 125,159,000 US dollars
- **Dividends to shareholders**: negative 376,465,000 US dollars
- **Contributions from non-controlling interests - other**: 4,360,000 US dollars
- **Distributions to legacy non-controlling interests - other**: 0 US dollars
- **Other**: negative 9,026,000 US dollars
- **Proceeds from issuance of long-term debt, net of discount**: 1,471,235,000 US dollars
- **Repayment of revolving credit facility**: 0 US dollars
- **Proceeds from revolving credit facility**: 0 US dollars
- **Contributions from legacy non-controlling interests - R&D**: 747,000 US dollars
- **Debt issuance costs and other**: negative 12,616,000 US dollars
- **Repurchases of Class A ordinary shares**: negative 229,651,000 US dollars
- **Cash acquired in connection with purchase of non-controlling interest**: 0 US dollars
- **Repayment of long-term debt**: 0 US dollars
- **Operating adjustment reconciliation**: 3,166,781,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
- **financing gross reconciliation**: 1,476,342,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
- **investing gross reconciliation**: 2,822,156,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
- **Exchange-rate effect**: 0 US dollars
- **Ending cash on Dec 31, 2024**: 929,026,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
- **Cash sources and uses**: 3,607,141,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
- **Net cash change**: 452,016,000 US dollars. Ending cash minus beginning cash.
- **Cash flow / Net income**: Unavailable. Operating cash flow and reconciliation net income for the same period are required.

### Chart connections

- Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
- Financing contributions meet at a reconciliation junction before connecting to the net cash total.
- Investing contributions meet at a reconciliation junction before connecting to the net cash total.
- Operating reconciliation adjustments are not all independent cash receipts.
- Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
- The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.